Printer Friendly

Kaneka Obtains Positive Results in Preclinical Trials of Drug Eluting Stent.

Tokyo, Japan, June 16, 2006 - (JCN) - Kaneka has obtained positive results from preclinical trials for a drug eluting stent (DES) that it is currently developing.

The Company commissioned Thoraxcenter, a hospital in the Netherlands, to conduct full-scale trials using pigs. The hospital confirmed that Kaneka's DES effectively inhibits blood vessel inflammation and endothelial proliferation. Furthermore, the DES helps accelerate the healing of endothelium. Based on these findings, Kaneka expects that the DES may substantially reduce the risk of stent thrombosis.

Kaneka's DES, which uses cobalt chromium alloy for a stent, consists of tacrolimus, an immunosuppressant by Astellas Pharma, and biodegradable polymer.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jun 16, 2006
Words:111
Previous Article:Ako Kasei Confirms that High Mineral Water Helps Suppress Helicobacter Pylori.
Next Article:Dainippon Sumitomo Pharma to Release AmBisome 50mg, Antifungal Agent for Deep-seated Mycosis Infection.


Related Articles
Medtronic Signs Strategic Agreements With Abbott Laboratories, Gains Access to Drug Compounds and Coating Technologies for Drug-Eluting Stent Program.
Guidant Signs Definitive Agreement to Acquire Biosensors' Everolimus Eluting Stent Assets.
Guidant Reports Positive Six-Month Clinical Results of Everolimus Eluting Coronary Stent; Data Supports Use of Everolimus for Drug Eluting Stents.
Guidant Reports Positive Results of Two Everolimus Eluting Coronary Stent Clinical Trials.
MIV Therapeutics Reports Successful Progress of Animal Studies on Proprietary Hydroxyapatite Coatings for Coronary Stents.
Cook to Begin First International Trial of a Paclitaxel-Eluting Stent for Peripheral Artery Disease; New Treatment Could Benefit Millions Who Suffer...
AVI BIOPHARMA INITIATES PHASE II CARDIOVASCULAR CLINICAL STUDY.
Preliminary Results from Duravest Subsidiary Estracure's Phase II Clinical Trial.
Preliminary Results from the Estracure Phase II Clinical Trial.
Guidant Announces Enrollment of First Patient in Clinical Trial of the World's First Fully Bioabsorbable Drug Eluting Coronary Stent; Innovative...

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters